Slide 1: SENTI-202 Initial Clinical Data
SENTI-202 Initial Clinical Data December 2024
Slide 2: Disclaimer: Forward Looking Statements
Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securities Litigation Reform Act of 1995. Statements we make in this presentation may include statements which are not histor
Slide 3: Corporate and Clinical Results Overview
SENTI-202 Initial Clinical Data Corporate and Clinical Results Overview Tim Lu, MD, PhD CEO and Co-Founder, Senti Biosciences 3
Slide 4: Senti's Gene Circuits Designed to Enhance Precision, Control, and Activity
Senti’s Gene Circuits Designed to Enhance Precision, Control, and Activity of Cell & Gene Therapies NK: Natural Killer; TME: Tumor Microenvironment 4 Multi-Arming Regulator Dial Smart Sensor Logic Gating Sense diseased vs healthy cells (e.g., SENTI-202) Stimulate immune cells, overcome TME, promote
Slide 5: Internal Focus on Oncology, Partnering to Support Non-Oncology Indications
Internal Focus on Oncology, Partnering to Support Non-Oncology Indications AML: Acute Myeloid Leukemia; CNS: Central Nervous System; HCC: Hepatocellular Carcinoma; MDS: Myelodysplastic Syndrome 1 Collaboration with Celest for clinical development to treat solid tumors in China, with an option to exp
Slide 6: SENTI-202 Potentially First-In-Class Selective Off-the-Shelf NK Cell Therapy
SENTI-202 Is a Potentially First-In-Class Selective Off-the-Shelf Investigational NK Cell Therapy for Blood Cancers 6 Logic Gating to overcome AML heterogeneity via clinically validated CD33 and FLT3 targets Logic Gating also to spare healthy cells via EMCN target, which is selectively expressed on
Slide 7: Unmet Need in Acute Myeloid Leukemia (AML)
SENTI-202 Initial Clinical Data Unmet Need in Acute Myeloid Leukemia (AML) Stephen A. Strickland, MD, MSCI Director of Leukemia Research, Sarah Cannon Research Institute 7
Slide 8: AML Is an Aggressive Leukemia with Poor Prognosis
AML Is an Aggressive Leukemia with Poor Prognosis Rapidly progressing blood cell cancer with clonal proliferation of leukemic blasts from myeloid lineage Initial treatment includes intensive chemotherapy followed by HCT for younger, fit patients and venetoclax/ HMA based therapy for older, unfit pat
Slide 9: Multiple Challenges to Developing Effective AML Therapies
There are Multiple Challenges to Developing Effective AML Therapies 1 Hansen Cancer Drug Resistance 2022 9 Durability of response is limited due to: Leukemic cell clonal heterogeneity which requires use of multi- targeted and combination therapies Leukemia stem cells (LSCs), a small population with
Slide 10: Deep Responses and Blood Count Recovery in AML Correlate with Longer Survival
Achieving Deep Responses and Blood Count Recovery in AML Correlates with Longer Survival 1 Dohner Blood 2022; 2 Innes Blood 2018 10 Detection of measurable residual disease (MRD) in patients with CR by conventional methods correlates with shorter remissions and poorer survival1 Measurement of MRD is
Slide 11: Clinical Trial Data
SENTI-202 Initial Clinical Data Clinical Trial Data Kanya Rajangam, MD, PhD President, Head of R&D and CMO, Senti Biosciences 11
Slide 12: SENTI-202 Potentially First-In-Class Selective Off-the-Shelf NK Cell Therapy
Cancer cellkilling Blast cell LSC FLT3 CD33 SENTI-202 Is a Potentially First-In-Class Selective Off-the-Shelf Investigational NK Cell Therapy for Blood Cancers 12 Activating CAR “kill” signal Bivalent CD33 and/or FLT3 CAR targets validated AML targets Potential for deep and durable responses in AML
Slide 13: Phase 1 Trial (SENTI-202-101) Design
SENTI-202 Phase 1 Trial (SENTI-202-101) Design1High starting dose based on NK tolerability profile designed to enable early efficacy signal detection DLT: Dose Limiting Toxicity; R/R: Relapsed Refractory 1 NCT06325748; 2 1-2 prior for MDS 13 Adult patients R/R CD33 and/or FLT3 expressing heme malign
Slide 14: SENTI-202-101 Clinical Study Program Overview
SENTI-202-101 Clinical Study Program OverviewEarly efficacy signals noted at the first dose level 14 Enrollment Dose Level 1 (1 billion CAR+ NK cells/dose) cleared: 3 R/R AML patients enrolled Dose Level 2 (1.5 billion CAR+ NK cells / dose) cohort actively enrolling Safety Data SENTI-202 is well tol
Slide 15: SENTI-202-101 Time on Study
SENTI-202-101 Time on StudyEarly efficacy signals noted at the first dose level, both CR patients continue in CR at 1+ month 15 NGS: Next-generation sequencing; MRD: measurable residual disease Data from an open clinical database of an ongoing study and PI/ site communication as of 19Sep2024
Slide 16: SENTI-202-101 Patient 1
SENTI-202-101 − Patient 1First Patient with CR after 2 cycles and clearance of all AML mutations by NGS Data from an open clinical database of an ongoing study and PI/ site communication 16 Blast reduction <5% for CR ANC: Absolute Neutrophil Count; PLT: Platelet Count Data from an open clinical data
Slide 17: SENTI-202-101 Patient 2
SENTI-202-101 − Patient 2Second Patient with MRD- CR by MRD flow cytometry after 1 cycle 17 72M with FLT3 mutated (intermediate risk) R/R AML that relapsed after intensive chemotherapy and FLT3 inhibitor SENTI-202 well tolerated with no DLT/ SAEs AEs include G4 hematologic toxicity consistent with l
Slide 18: Initial Correlative Data
SENTI-202 Initial Correlative DataSENTI-202 is detected in the peripheral blood across all patients 18 Copies/μg DNA Time (Days) LLOQ Copies/μg DNA SENTI-202 doses SENTI-202 pharmacokinetics across 3 patients Interim data as of 19 Sep2024 Nominal value of 1 assigned for timepoints with non-measurabl
Slide 19: Mechanism of Action and Early Clinical Results are Promising Indicators
SENTI-202 Mechanism of Action and Early Clinical Results are Promising Indicators of a Differentiated Clinical Profile 19 Durability data in 2025 SENTI-202 is designed to integrate validated mechanisms into one solution,engineered to solve key outstanding problems in AML Anticipated Clinical Catalys
Slide 20: Executing Towards Bringing Gene Circuit Medicines to Patients
Executing Towards Bringing Gene Circuit Medicines to Patients 20 T cells AAVs IPSCs & Other Modalities NK cells Gene Circuit SENTI-202 is a potential first-in-class logic gated CAR-NK program for AML Initial cohort data demonstrates evidence of efficacy and safety SENTI-301A first patient expected t
Slide 21: Q&A
SENTI-202 Initial Clinical Data Q&A 21